Europe (WHO region) vs Oman: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Europe (WHO region)
83.0%
in 2025
Oman
99.0%
in 2025
Europe (WHO region) rank
3rd
Oman rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Europe (WHO region)
- Oman
How they compare
Oman currently reports 99.0% against 83.0% in Europe (WHO region), a difference of 16.0%.
That makes Oman's figure about 1.2 times Europe (WHO region)'s.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Europe (WHO region) ahead.
Europe (WHO region) ranks 3rd and Oman ranks 1st of 11 groups.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 15.5% | 48.0% | 32.5% | Oman |
| 2010s | 54.4% | 98.8% | 44.4% | Oman |
| 2020s | 81.8% | 98.7% | 16.8% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Europe (WHO region) or Oman?
- Oman, at 99.0% against 83.0% in Europe (WHO region) as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Europe (WHO region) and Oman?
- 16.0%, with Oman ahead.
- How many years of comparable data are there for Europe (WHO region) and Oman?
- 18 years are reported by both, from 2008 to 2025.
- How do Europe (WHO region) and Oman rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Europe (WHO region) ranks 3rd and Oman ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.